Team & Partners
Based at the in Dallas at BioLabs @ Pegasus Park (the new ARPA-H Hub Headquarters), BioLum Sciences has deep expertise in small molecule organic and inorganic probes & synthesis for bioanalyte detection via chemiluminescent, colorimetric, and fluorescent assays. We have assembled a qualified team of specialist partners including analytical chemists, electrical engineers, and medical device developers. Along with this, we have a robust advisory network that includes healthcare executives, commercialization specialists, pulmonologists, sales leaders, legal and regulatory counsel.
BioLum was recently recognized as 1 of 6 ‘Rising Stars’ at the BioNTX iC3 Life Science Summit (2022 winners: Lantern Pharma, Colossal, Evolve Biologics, and NemaLife) spotlighting North Texas based firms demonstrating potential to transform the healthcare landscape with cutting-edge research. We are dedicated to advancing precision medicine and health outcomes by advancing reliability in biomarker detection for both research and clinical applications.
Jack Reynolds - CEO
After dealing with exercise-induced asthma as a tennis player, and recently, an unprovoked DVT (deep vein thrombosis - 3rd most common vascular disease), Reynolds has a deep connection to chronic disease and remains determined to drive positive change in both drug discovery and disease management. He has experience at early-stage and large corporations including positions at a fintech company (BankLabs), a hedge fund (Madison Street Partners), foreign currency brokerage (FXCM), Kingsley Advisors, and other startup ventures of his own. He holds a B.B.A. in Finance & B.A. in Markets & Culture from Cox School of Business at Southern Methodist University.
Dr. Alex Lippert, PhD - CSO
Dr. Lippert is a PhD chemist with 20 years of expertise in synthetic chemistry and development of colorimetric fluorescent & chemiluminescent techniques for imaging biological analytes in living cells, animals, and clinical samples. He has five patents, more than 40 publications, and serves as PI on several grants awarded by the National Institutes of Health and various other agencies. Alex's scientific knowledge and mindset has been a strong driving force for BioLum's product development, experimental design, and project execution.
Dr. Husain Kagalwala - CTO
Dr. Kagalwala has a background in developing small molecule organic and inorganic chemiluminescent probes for bioanalyte detection, as well as photosensitizers and catalysts for renewable energy conversion applications. He obtained his Ph.D. from Carnegie Mellon University in 2015 and was recently a postdoctoral researcher at Southern Methodist University. He has published more than 20 scientific articles and multiple patents to date. Dr. Kagalwala leads BioLum’s ongoing research and assay development.
Partners
Partnership and collaboration are critical components of innovation, especially in the healthcare and life sciences industries. BioLum is focused on partnering with academic institutions and corporate leaders in biotechnology, pharmaceuticals, and diagnostics. Our mission has resonated with many individuals and organizations. We welcome new partnerships as we continue to grow our technology and company. As our company has grown from Dallas, Houston, Germany, and San Diego, we've formed key relationships that play important roles as we build and grow. By developing robust partnerships with local and global collaborators, we amplify scientific insights and mechanistic understandings, building upon our evidence base, while de-risking long-term commitment to clinical PoC IVD solutions for early diagnosis, patient stratification, and precision medicine
Mina Abadir - Alliance Officer
Mina Abadir has over 27 years’ experience in Life Science Industry with experience in business development, transaction execution, clinical trial development, M&A and licensing. Led several innovative start-ups in helping prepare for IPOs, mergers, partnerships, alliances & FDA approvals. Worked and consulted in top pharmas (Pfizer, Merck, Johnson & Johnson, Novartis, Sanofi, AbbVie, BMS, Bayer & Roche). Highly respected & connected with C-level in the pharma & VC communities. Led large multi-functional Alliance Management & due diligence team to evaluate out-licensing and in-licensing activities.
